Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 13/20 | 0.43 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912115 | 1.00 | AR (0.43) | ARFFAR2ELOVL1SYKGRIA1 | |
| SCHEMBL23344656 | 0.86 | AR (0.42) | ARFFAR2ELOVL1SYKACACB | |
| SCHEMBL30912117 | 0.79 | FFAR2 (0.43) | FFAR2 | |
| SCHEMBL23328039 | 0.79 | FFAR2 (0.43) | FFAR2 | |
| SCHEMBL3296150 | 0.79 | MAP4K4 (0.41) | — | |
| SCHEMBL3287525 | 0.76 | CYP1A2 (0.52) | — | |
| SCHEMBL3288392 | 0.76 | PDE10A (0.43) | — | |
| SCHEMBL31696829 | 0.74 | AR (0.51) | ARFFAR2ELOVL1SYK | |
| SCHEMBL3291005 | 0.72 | GRM4 (0.43) | — | |
| SCHEMBL3289773 | 0.72 | KMT2A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | LIEBER INSTITUE, INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139456-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN5A, SCN2A | AR 4717/4885FFAR2 4053/4885ELOVL1 3046/4885 |
| US-11993581-B2 | Pyridazine compounds for inhibiting Nav1.8 | SCN8A, SCN5A, SCN2A | AR 4717/4885FFAR2 4053/4885ELOVL1 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.